Unicycive Therapeutics, Inc. - Common Stock (UNCY)
0.5730
-0.3270 (-36.33%)
NASDAQ · Last Trade: Jun 10th, 2:05 PM EDT
Detailed Quote
Previous Close
0.9000
Open
0.4980
Bid
0.5729
Ask
0.5730
Day's Range
0.4700 - 0.7300
52 Week Range
0.2020 - 1.100
Volume
41,943,318
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,289,228
Chart
About Unicycive Therapeutics, Inc. - Common Stock (UNCY)
Unicycive Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the areas of kidney diseases. The company is primarily engaged in creating novel drug candidates that enhance the management of renal conditions, aiming to improve patient outcomes through targeted treatments. By leveraging its expertise in drug development and its commitment to scientific research, Unicycive Therapeutics seeks to bring forth new solutions that can significantly impact the lives of individuals suffering from various kidney-related disorders. Read More
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Unicycive Therapeutics (NASDAQ: UNCY) is at the forefront of developing cutting-edge therapies for kidney diseases. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.
